Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

SHILPA MEDICARE LTD. - 530549 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Further to our letter dated 11th November 2022 regarding approval of Un-audited Standalone and Consolidated Financial Results of the Company for the quarter & half year ended 30th September 2022, please find enclosed newspaper advertisements, published in compliance with Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in Soodhimool (Kannada) and Business Line (English) on 13th November 2022.
14-11-2022
Bigul

SHILPA MEDICARE LTD. - 530549 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

 Pursuant to Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and further to our letter dated 12th November 2022, please note that the audio recording of the conference call for Investors/Analysts for the discussion on Q2 & H1 FY23 results, held on 14th November 2022, at 11.30 AM(IST), has been uploaded on our website.
14-11-2022
Bigul

SHILPA MEDICARE LTD. - 530549 - Announcement under Regulation 30 (LODR)-Investor Presentation

 With reference to the captioned subject, the Investor Presentation of the Company for the Second Quarter & half year ended 30 September 2022 with regard to Business highlights, financial performance and other updates is attached herewith for your consideration.
13-11-2022
Bigul

SHILPA MEDICARE LTD. - 530549 - Appointment Of O3 Capital Global Advisory Private Limited

 Pursuant to the fund raising plan of the Shilpa Pharma Lifesciences Ltd (SPL), a wholly owned subsidiary of the Company, operating in Active Pharmaceutical Ingredient(s) business, we wish to inform you that SPL has appointed o3 Capital Global Advisory Private Limited, an Investment Bank to evaluate various monetization options for SPL including fund raising from potential investors. This announcement is in furtherance to the earnings calls addressed by the Company on 30th August 2022, wherein the management has addressed the queries clarifying that company was evaluating various options to monetize the API business
12-11-2022
Bigul

SHILPA MEDICARE LTD. - 530549 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Pursuant to Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the schedule of Q2 & H1 FY23 Conference Call to be held on Monday, November 14, 2022 at 11:30 AM IST.
12-11-2022
Bigul

SHILPA MEDICARE LTD. - 530549 - Board Meeting Outcome for Outcome Of Board Meeting

 With reference to the subject cited above, this is to intimate that the Board of Directors at their meeting held on 11th November 2022 which commenced at 02.00 p.m. and concluded at 05. oo p.m. have inter alia considered and approved Un-Audited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30 September 2022.
11-11-2022

Shilpa Medicare plans API biz stake sale

 Shilpa Medicare had a market capitalization of 2,720 crore at close of trading on Monday. The company generates bulk of its revenue from the API business
08-11-2022
Bigul

SHILPA MEDICARE LTD. - 530549 - Board Meeting Intimation for Intimation Of Board Meeting To Consider The Un-Audited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended 30Th September 2022

 SHILPA MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2022 ,inter alia, to consider and approve the Un-audited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended 30th September 2022.
03-11-2022
Bigul

SHILPA MEDICARE LTD. - 530549 - Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations, 2015

 With reference to our intimation dated 22 October 2022 with regard to the reporting of violation of Code of conduct for prohibition of Insider trading, We would like to inform Mr. Suraj innani has paid the penalty amount Rs. 25000/- to the Company and the Company has deposited the said amount to SEBI (Investor Protection and Education Fund) on 26 October 2022 vide UTR no 10516FZ01XVN.
28-10-2022
Bigul

SHILPA MEDICARE LTD. - 530549 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

 The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Pivotal Enterprises Pvt Ltd & PACs
27-10-2022
Next Page
Close

Let's Open Free Demat Account